HTA168 Data Maturity and Treatment Positioning to Support Reimbursement: The Case for Siltuximab (SYLVANT®) in Australia
Abstract
Authors
F Shupo K Abrams Z Ademi G Wayi-Wayi N Zibelnik M Kirchmann C Rutherford P Holko P Kawalec K Makarounas-Kirchmann